News

Global pharma company Thermo Fisher Scientific has announced the launch of CorEvitas Adolescent Alopecia Registry, which aims to address an unmet need in the research for adolescent alopecia.

Research in treatments for alopecia areata (AA) – an autoimmune disease that causes part or full hair loss across the body, including most notably the scalp – suffers from a lack of real-world evidence. Adolescents in particular are affected by the lack of real-world evidence. According to Thermo Fisher, the registry seeks to counteract this by collecting multiple data points surrounding AA, including ‘the incidence of safety events… medication utilisation patterns, and the comparative safety and effectiveness of treatments’, according to the announcement.

Following a similar adult-focused registry launched by CorEvitas in 2023, the registry is the 12th independent medical registry that the company has run. Both AA registries have been guided in their development by dermatology experts at Yale School of Medicine, Harvard Medical School and the Dermatology Physicians of Connecticut, in the US.

Peter Wahl ScD, global head of Scientific Affairs, CorEvitas clinical research, Thermo Fisher Scientific stated: “This first-of-its-kind registry will provide researchers with real-world, concrete evidence about the health status and treatment patterns of these patients. The research community will be able to contextualise both the effectiveness and safety of newly approved treatments for adolescents with AA.”